A $6.8 Million ASC Joint Venture with Physicians: NPV, Cannibalization, and Structure
Lakeshore Health (three hospitals, $1.4 billion net revenue, 501(c)(3), WACC 8.5%) is deciding whether to build a $6.8 million ambulatory surgery center in a fast-growing suburb. The system would own 60%; eight surgeons would hold the remaining 40% through a single LLC, contributing $2.72 million at closing. The business case assumes 2,800 cases in year 1, 4,500 in year 2, 6,000 in year 3, and 3% growth thereafter, at $2,450 average net revenue per case and $1,300 variable cost per case. Fixed operating cost is $4.6 million in year 1 and grows 3% per year. Lakeshore uses a 10-year analysis with a terminal value of 8.0 times year-10 EBITDA. Roughly 30% of the projected year-3 volume currently flows through Lakeshore's hospital outpatient department, where contribution margin averages $2,600 per case, and the hospital outpatient department has capacity to backfill only about half of that with other cases. A competing system has optioned land two miles away.
1. Build the cash flows and compute NPV and IRR. Is the project viable on a standalone basis?
Read the worked answer
Per-case economics. Contribution margin = $2,450 - $1,300 = $1,150 per case.
EBITDA by year (cases x $1,150 less fixed cost).
- Year 1: 2,800 x $1,150 = $3,220,000 - $4,600,000 = -$1,380,000
- Year 2: 4,500 x $1,150 = $5,175,000 - $4,738,000 = $437,000
- Year 3: 6,000 x $1,150 = $6,900,000 - $4,880,000 = $2,020,000
- Year 4: $2,080,000; Year 5: $2,143,000; Year 6: $2,207,000; Year 7: $2,273,000; Year 8: $2,342,000; Year 9: $2,412,000; Year 10: $2,484,000
Discounting at 8.5%. Present value of operating cash flows is about $9.72 million. Terminal value = 8.0 x $2,484,000 = $19.87 million, present value $8.79 million. Total present value $18.51 million less the $6.8 million outlay = NPV of about $11.7 million. IRR is roughly 22%, well above the 8.5% WACC.
Standalone verdict: viable. But state the caveats rather than stopping at the number. The result is exquisitely sensitive to volume: the project is EBITDA-negative in year 1 and does not clear its fixed cost until roughly 4,000 cases, which is 620 cases above the year-2 plan. A 15% shortfall against the year-3 case target cuts terminal EBITDA by roughly $440,000 and the terminal value by $3.5 million. The terminal value is 45% of total present value, so the exit multiple assumption drives much of the answer. Test at 6.0x and 10.0x, and test a 10-year versus 15-year horizon. The base case is fundable; the question is whether the system should fund it for the reasons the pro forma implies.
2. Quantify the cannibalization and revise the recommendation. Does the answer change?
Read the worked answer
The standalone NPV hides the real economics. The system is a consolidated entity; it does not get to keep the ASC margin and ignore the outpatient department's lost margin.
Steady state (year 3+).
- Diverted volume: 30% x 6,000 = 1,800 cases
- Backfill: half, or 900 cases, replaced in the hospital outpatient department at similar margin - so no loss on those
- Unbackfilled: 900 cases x $2,600 lost contribution = $2,340,000 per year
- System's 60% share of ASC EBITDA in year 3: 0.60 x $2,020,000 = $1,212,000
- Net system effect: $1,212,000 - $2,340,000 = about -$1,128,000 per year
So the consolidated project is value-destroying at steady state even though the standalone NPV is positive. The standard pro forma, built on the ASC's own P&L, answers the wrong question.
But the recommendation does not flip to no. Compare build against the realistic alternative, not against nothing:
- Build: net cost of about $1.13 million per year
- Do not build, competitor captures the 1,800 cases: lose the full 1,800 x $2,600 = $4.68 million per year, with no ASC margin at all
Building is roughly $3.5 million per year better than losing the cases outright. The project's true justification is defensive and strategic, not the 22% IRR. That framing changes the negotiating posture: the system should push for a larger ownership share, a slower migration of cases out of the hospital outpatient department, a location or service-line carve-out that protects the highest-margin inpatient and hospital outpatient cases, and physician distribution terms that reward case volume at the ASC. Present the board with both the standalone and the consolidated analysis and say explicitly which one drove the decision.
3. What has to be true about the physician investment structure before this closes?
Read the worked answer
Two federal regimes apply at once. The Anti-Kickback Statute and the physician self-referral (Stark) law both reach a hospital that gives physicians an ownership stake in an entity to which they refer. Two exceptions are relevant and each has specific conditions: the ASC safe harbor at 42 CFR 1001.952(r) under the AKS, and the surgeon-investment ASC exception under Stark. Neither is satisfied by good intentions, and the operative text should be confirmed with healthcare counsel against the current regulation before signing - the conditions are detailed and have been amended.
The structural conditions to verify.
- The ASC is Medicare-certified and the investment is in the entity that owns and operates the ASC, not in a separate equipment or staffing entity that leases to it.
- Returns are proportional to ownership; no physician gets a return tied to the volume or value of referrals, and no productivity-based distributions.
- The hospital does not guarantee, require, or encourage referrals, and no physician is required to refer.
- Investment terms are identical across investors, including the price per unit, and the ASC does not loan money to physicians to fund their contributions.
- The physicians actually perform a meaningful share of their procedures at the ASC.
- Fair market value documentation for the ownership units, independent of any referral value.
Tax-exempt considerations. A 501(c)(3) system that shares ownership and profits with referring physicians must confirm the arrangement serves a charitable purpose, does not confer private benefit or inurement beyond FMV, and is disclosed appropriately on Form 990 Schedule L. The 60/40 split means the system consolidates the LLC and reports a noncontrolling interest.
Governance. Any board member, officer, or employed physician with a financial interest must be recused from the vote. The board resolution should record the FMV opinion, the counsel opinion, and the strategic rationale, including the defensive case, so the file supports the decision if it is ever examined.